A1 Refereed original research article in a scientific journal
Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance
Authors: Nevo J, Mattila E, Pellinen T, Yamamoto DL, Sara H, Iljin K, Kallioniemi O, Bono P, Heikkila P, Joensuu H, Warri A, Ivaska J
Publisher: AMER ASSOC CANCER RESEARCH
Publication year: 2009
Journal: Clinical Cancer Research
Journal name in source: CLINICAL CANCER RESEARCH
Journal acronym: CLIN CANCER RES
Volume: 15
Issue: 21
First page : 6570
Last page: 6581
Number of pages: 12
ISSN: 1078-0432
DOI: https://doi.org/10.1158/1078-0432.CCR-09-0773
Abstract
Conclusions: MDGI-driven inherent desensitization of cancer cells is a novel molecular mechanism for resistance to the anti-EGFR antibody therapy, and MDGI may be a biomarker for responsiveness to anti-EGFR antibody therapy. (Clin Cancer Res 2009;15(21):6570-81)
Conclusions: MDGI-driven inherent desensitization of cancer cells is a novel molecular mechanism for resistance to the anti-EGFR antibody therapy, and MDGI may be a biomarker for responsiveness to anti-EGFR antibody therapy. (Clin Cancer Res 2009;15(21):6570-81)